<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662454</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU FAMPLAN 0411</org_study_id>
    <secondary_id>NIH R03 HD053611 01</secondary_id>
    <nct_id>NCT00662454</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive Efficacy and Body Weight</brief_title>
  <official_title>Oral Contraceptive Efficacy and Body Weight: Does Obesity Affect the Risk of Contraceptive Failure?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Clinical and Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the blood spot validation portion of the study is to test if measuring female&#xD;
      hormone levels in the blood is as accurate through a finger stick, as it is by a blood draw&#xD;
      from a vein. The purpose of the feasibility study is to evaluate ovulation occurrence in two&#xD;
      populations of oral contraceptive users: heavier and lighter women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The blood spot validation portion of the study tests the hypothesis that progesterone assays&#xD;
      from self-collected daily blood spots are equivalent to serum samples, and that the values&#xD;
      obtained can identify women that ovulate. After validating collection methods, enrollment&#xD;
      will begin for the feasibility portion of the study looking at thin and heavy women on birth&#xD;
      control pills. All women in this portion of the study will take a very-low dose birth control&#xD;
      pill that is normally available through a doctor's office. During each month of the study,&#xD;
      women will have their blood pressure and weight recorded, and have their blood drawn twice&#xD;
      per week or use a finger stick kit daily at home to check for the natural hormones and brain&#xD;
      chemicals that tells if an egg develops. During the last week of each menstrual cycle (period&#xD;
      week), women will also have their blood drawn to measure the levels of hormone found in the&#xD;
      birth control pill. Women will also need to report in a written diary that they have taken&#xD;
      their birth control pill for the day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of circulating oral contraceptives dosed in a standard cyclic fashion in obese and normal BMI cohorts</measure>
    <time_frame>Approximately one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Contraception</condition>
  <condition>Body Weight</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 normal weight women (BMI &lt; 25 kg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 obese women (BMI &gt;30 kg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol / levonorgestrel</intervention_name>
    <description>Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Alesse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol / levonorgestrel</intervention_name>
    <description>Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Alesse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 to 35&#xD;
&#xD;
          -  single baseline hematocrit â‰¥ 36%&#xD;
&#xD;
          -  single progesterone level of 3 ng/mL or greater during the luteal phase (days 18 to&#xD;
             25) in the menstrual cycle prior to treatment with OCs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any absolute contraindications to ethinyl estradiol and levonorgestrel&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  actively seeking or involved in a weight loss program (must be weight stable)&#xD;
&#xD;
          -  pregnancy, breastfeeding, or seeking pregnancy&#xD;
&#xD;
          -  diagnosis of Polycystic Ovarian Syndrome&#xD;
&#xD;
          -  recent (8 week) use of OC (patch or ring included), intrauterine, or implantable&#xD;
             hormonal contraception&#xD;
&#xD;
          -  DepoProvera use within six months&#xD;
&#xD;
          -  current use of drugs that interfere with metabolism of sex steroids.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Edelman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsuwomenshealth.com/research/index.html</url>
    <description>OHSU Women's Health Research Unit</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>contraceptive</keyword>
  <keyword>efficacy</keyword>
  <keyword>body weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

